OX2 Therapeutics
Mound, US · Founded 2016 · Delaware corporation
Founders & leadership
SD
Sumant DhawanExecutive
JL
Jeff LiterExecutive
MO
Mike OlinNamed on SEC filing
CM
Christopher MoertelNamed on SEC filing
Board
BO
Ben OehlerBoard director
TM
Thomas MartinsonBoard director
Reported raises · per SEC filings
Form D private placements$954.4K disclosed across 2 rounds · 2017–2020
▶$649.4KraisedSep 2020 · 15 investors · BiotechnologyRule 506(b)
▶$649.4KraisedSep 2020 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rob ParishDirector
- Ben OehlerDirector
- Christopher MoertelExecutive Officer, Director
- Jeff LiterExecutive Officer, Promoter
- Andrea HuntDirector
- Mike OlinExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $649.4K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$305KraisedMay 2017 · 4 investors · BiotechnologyRule 506(b)
▶$305KraisedMay 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mike OlinDirector
- Ben OehlerDirector
- Sumant DhawanExecutive Officer, Director
- Christopher MoertelDirector
- Jeff LiterExecutive Officer, Promoter
- Thomas MartinsonDirector
- Offering amount
- $3.1M
- Amount sold
- $305K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has OX2 Therapeutics raised?
- OX2 Therapeutics has disclosed $954.4K raised across 2 rounds.
- Where is OX2 Therapeutics headquartered?
- OX2 Therapeutics is headquartered in Mound, US.